GCM
EW icon

Geneva Capital Management’s Edwards Lifesciences EW Stock Holding History

Geneva Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
18,377
-2,866
-13% -$240K 0.04% 110
2026
Q1 		$1.7M Buy
21,243
+4,091
+24% +$337K 0.04% 112
2025
Q4 		$1.46M Buy
17,152
+3,201
+23% +$263K 0.03% 120
2025
Q3 		$1.08M Sell
13,951
-528
-4% -$41.3K 0.02% 121
2025
Q2 		$1.13M Sell
14,479
-483
-3% -$36K 0.02% 122
2025
Q1 		$1.08M Sell
14,962
-268
-2% -$19.2K 0.02% 123
2024
Q4 		$1.13M Sell
15,230
-1,092
-7% -$76.4K 0.02% 128
2024
Q3 		$1.08M Sell
16,322
-1,415
-8% -$103K 0.02% 129
2024
Q2 		$1.64M Sell
17,737
-4,421
-20% -$391K 0.03% 125
2024
Q1 		$2.12M Sell
22,158
-1,104
-5% -$92.7K 0.04% 120
2023
Q4 		$1.77M Sell
23,262
-1,165
-5% -$81.1K 0.03% 121
2023
Q3 		$1.69M Sell
24,427
-9,378
-28% -$754K 0.04% 120
2023
Q2 		$3.19M Sell
33,805
-1,423
-4% -$124K 0.06% 111
2023
Q1 		$2.91M Sell
35,228
-2,622
-7% -$206K 0.06% 112
2022
Q4 		$2.82M Buy
37,850
+1,289
+4% +$99.3K 0.06% 114
2022
Q3 		$3.02M Sell
36,561
-12
-0% -$1.16K 0.07% 116
2022
Q2 		$3.48M Sell
36,573
-403
-1% -$41.7K 0.08% 112
2022
Q1 		$4.35M Buy
36,976
+420
+1% +$47.1K 0.08% 113
2021
Q4 		$4.74M Sell
36,556
-893
-2% -$104K 0.08% 114
2021
Q3 		$4.24M Sell
37,449
-1,083
-3% -$124K 0.07% 114
2021
Q2 		$3.99M Sell
38,532
-167
-0.4% -$15.7K 0.07% 115
2021
Q1 		$3.24M Buy
38,699
+4,529
+13% +$383K 0.06% 119
2020
Q4 		$3.12M Buy
34,170
+36
+0.1% +$2.99K 0.05% 120
2020
Q3 		$2.73M Buy
34,134
+309
+0.9% +$24.1K 0.06% 116
2020
Q2 		$2.34M Buy
33,825
+300
+0.9% +$21.3K 0.05% 115
2020
Q1 		$2.11M Buy
+33,525
New +$2.42M 0.06% 115
2013
Q4 		– Sell
-3,055,296
Closed -$35.5M – 137
2013
Q3 		$35.5M Sell
3,055,296
-1,329,936
-30% -$15.6M 0.84% 55
2013
Q2 		$49.1M Buy
+4,385,232
New +$51.9M 0.98% 51

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Geneva Capital Management's EW Position: Q2 2026 in Review

Geneva Capital Management reduced its Edwards Lifesciences (EW) stake by 13% in Q2 2026, selling an estimated $240K and leaving 18,377 shares worth $1.66M. The position accounts for 0.04% of the portfolio, ranked #110.

Geneva Capital Management first reported a position in EW in Q2 2013 and has held it in 28 quarters since. The position peaked at $49.1M in Q2 2013. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Geneva Capital Management held 18,377 shares of Edwards Lifesciences worth $1.66M as of Q2 2026.
  • Geneva Capital Management sold 2,866 Edwards Lifesciences shares in Q2 2026, an estimated $240K.
  • Edwards Lifesciences made up 0.04% of Geneva Capital Management's portfolio in Q2 2026, its #110 holding.
  • Geneva Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 28 quarters since.
  • Geneva Capital Management's Edwards Lifesciences position peaked at $49.1M in Q2 2013.
  • 1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.